Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: Results of 4 German centers

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 3, 2012, Pages 191-196

  Oehrlein, Katharina ^a   Langer, Christian ^b   Sturm, Isrid ^c   Pönisch, Wolfram ^d   Hahn Ast, Corinna ^e   Kuhn, Sigrid ^f   Weisel, Katja C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f Celgene GmbH   (Germany)

Author keywords

Creatinine clearance; Lenalidomide; Multiple myeloma; Relapse; Renal impairment

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; LIVER ENZYME;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GERMANY; HEMODIALYSIS PATIENT; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; PAIN; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84861075143     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.01.001     Document Type: Article

References (25)

1. R. Alexanian, B. Barlogie, D. Dixon Renal failure in multiple myeloma Pathogenesis and prognostic implications Arch Intern Med 150 1990 1693 1695 (Pubitemid 20240982)
2. J. Bladé, P. Fernandez-Llama, F. Bosch Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution Arch Intern Med 158 1998 1889 1893 (Pubitemid 28440861)
3. R.A. Kyle, M.A. Gertz, T.E. Witzig Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33 (Pubitemid 36033957)
4. L.M. Knudsen, M. Hjorth, E. Hippe Renal failure in multiple myeloma: reversibility and impact on the prognosis Nordic Myeloma Study Group Eur J Haematol 65 2000 175 181
5. M.A. Dimopoulos, E. Kastritis, L. Rosinol Pathogenesis and treatment of renal failure in multiple myeloma Leukemia 22 2008 1485 1493
6. J. Bladé, L. Rosinol Renal, hematologic and infectious complications in multiple myeloma Best Pract Res Clin Haematol 18 2005 635 652 (Pubitemid 40984119)
7. P.W. Sanders, B.B. Booker Pathobiology of cast nephropathy from human Bence Jones proteins J Clin Invest 89 1992 630 639
8. M.A. Dimopoulos, E. Terpos, A. Chanan-Khan Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group J Clin Oncol 28 2010 4976 4984
9. M.A. Dimopoulos, E. Terpos Renal insufficiency and failure Hematology Am Soc Hematol Educ Program 2010 2010 431 436
10. E. Kastritis, A. Anagnostopoulos, A. Dimopoulos Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents Haematologica 92 2007 546 549 (Pubitemid 350144300)
11. S.M. Korbet, M.M. Schwatz Multiple myeloma J Am Soc Nephrol 17 2006 2533 2545 (Pubitemid 44300969)
12. K. Weisel, M. Hänel, U. Dührsen Speed of response with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: first results of the MM-019 German compassionate use protocol Haematologica 94 suppl 2 2009 160 abstr 0397
13. D.M. Weber, C. Chen, R. Niesvizky Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2007 2133 2142 (Pubitemid 350146108)
14. M. Dimopoulos, A. Spencer, M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2007 2123 2132 (Pubitemid 350146107)
15. M.A. Dimopoulos, C. Chen, A. Spencer Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma Leukemia 23 2009 2147 2152
16. N. Chen, H. Lau, L. Kong Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis J Clin Pharmacol 47 2007 1466 1475 (Pubitemid 350115306)
17. M.A. Dimopoulos, A. Alegre, E.A. Stadtmauer The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Cancer 116 2010 3807 3814
18. M.A. Dimopoulos, D. Christoulas, M. Roussou Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment Eur J Haematol 85 2010 1 5
19. U. Klein, K. Neben, T. Hielscher Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment Ann Hematol 90 2011 429 439
20. J. De la Rubia, M. Roig, A. Ibáñez Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study Eur J Haematol 85 2010 363 365
21. REVLIMID (Lenalidomide) [Summary of Product Characteristics] 2011 Celgene Europe Limited Uxbridge, UK
22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Available at: http://ctep.cancer.gov/.
23. A. Palumbo, S.V. Rajkumar, M.A. Dimopoulos Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423 (Pubitemid 351255436)
24. J.F. San Miguel, P.G. Richardson, P. Sonneveld Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study Leukemia 22 2008 842 849 (Pubitemid 351552634)
25. J. Bladé, P. Sonneveld, J.F. San Miguel Pegylated liposomal doxorubicin plus bortezomib in relapsed and/or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment Clin Lymphoma Myeloma 8 2008 352 355